Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X_L-Specific Degrader DT2216.

ABSTRACT: Pancreatic cancer is the third most common cause of cancer-related deaths in the United States. Although gemcitabine is the standard of care for most patients with pancreatic cancer, its efficacy is limited by the development of resistance. This resistance may be attributable to the evasion of apoptosis caused by the overexpression of BCL-2 family antiapoptotic proteins. In this study, we investigated the role of BCL-X_L in gemcitabine resistance to identify a combination therapy to more effectively treat pancreatic cancer. We used CRISPR-Cas9 screening to identify the key genes involved in gemcitabine resistance in pancreatic cancer. Pancreatic cancer cell dependencies on different BCL-2 family proteins and the efficacy of the combination of gemcitabine and DT2216 (a BCL-X_L

SUBMITTER: Thummuri D 

PROVIDER: S-EPMC8742767 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature